Literature DB >> 1853412

Magnesium sulfate reverses experimental delayed cerebral vasospasm after subarachnoid hemorrhage in rats.

Z Ram1, M Sadeh, I Shacked, A Sahar, M Hadani.   

Abstract

We induced experimental delayed cerebral vasospasm by the intracisternal injection of greater than 0.5 ml blood in 30 rats. Seventy-two hours later the basilar artery was exposed via the transclival approach and photographed at high-power magnification through an operating microscope. We then evaluated the effect of topical (n = 30) and intravenous (n = 20) magnesium sulfate on the spastic artery by computerized image analysis. A greater than 50% reduction in baseline diameter of the basilar artery was observed in the rats subjected to subarachnoid hemorrhage compared with the 10 controls (p less than 0.0001). Intravenous magnesium sulfate dilated the spastic artery to approximately 75% of the baseline diameter in control rats (p less than 0.0001). Topical magnesium sulfate caused dramatic dilation of the basilar artery in both the control and the subarachnoid hemorrhage groups to near 150% of the baseline diameter in the controls (p less than 0.001). All rats receiving intravenous magnesium sulfate reached therapeutic plasma levels of the ion. Hemodynamic effects were mild and immediately reversible upon cessation of magnesium sulfate administration. We suggest that magnesium has a role in the treatment of subarachnoid hemorrhage-induced vasospasm in humans.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1853412     DOI: 10.1161/01.str.22.7.922

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  22 in total

1.  The safety and feasibility of continuous intravenous magnesium sulfate for prevention of cerebral vasospasm in aneurysmal subarachnoid hemorrhage.

Authors:  Abutaher M Yahia; Jawad F Kirmani; Adnan I Qureshi; Lee R Guterman; L Nelson Hopkins
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 2.  Magnesium neuroprotection is limited in humans with acute brain injury.

Authors:  J Andrew McKee; Randall P Brewer; Gary E Macy; Cecil O Borel; James D Reynolds; David S Warner
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 3.  Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema.

Authors:  W S Bartynski
Journal:  AJNR Am J Neuroradiol       Date:  2008-04-10       Impact factor: 3.825

Review 4.  Treatment options for cerebral vasospasm in aneurysmal subarachnoid hemorrhage.

Authors:  M Kamran Athar; Joshua M Levine
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

5.  Magnesium Sulfate Provides Neuroprotection in Eclampsia-Like Seizure Model by Ameliorating Neuroinflammation and Brain Edema.

Authors:  Xiaolan Li; Xinjia Han; Jinying Yang; Junjie Bao; Xiaodan Di; Guozheng Zhang; Huishu Liu
Journal:  Mol Neurobiol       Date:  2016-11-22       Impact factor: 5.590

6.  Serum magnesium levels as related to symptomatic vasospasm and outcome following aneurysmal subarachnoid hemorrhage.

Authors:  Frederic P Collignon; Jonathan A Friedman; David G Piepgras; Mark A Pichelmann; Jon I McIver; L Gerard Toussaint; Robyn L McClelland
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

Review 7.  Magnesium for neuroprotection in ischaemic stroke: rationale for use and evidence of effectiveness.

Authors:  K W Muir
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 8.  Smooth muscle phenotype switching in blast traumatic brain injury-induced cerebral vasospasm.

Authors:  Eric S Hald; Patrick W Alford
Journal:  Transl Stroke Res       Date:  2013-11-07       Impact factor: 6.829

9.  Magnesium sulfate treatment in experimental spinal cord injury: emphasis on vascular changes and early clinical results.

Authors:  Erkan Kaptanoglu; Etem Beskonakli; Ihsan Solaroglu; Asuman Kilinc; Yamac Taskin
Journal:  Neurosurg Rev       Date:  2003-05-29       Impact factor: 3.042

10.  Magnesium sulfate treatment improves outcome in patients with subarachnoid hemorrhage: a meta-analysis study.

Authors:  Bin Huang; Nikan H Khatibi; Linyan Tong; Pengcheng Yan; Peng Xie; John H Zhang
Journal:  Transl Stroke Res       Date:  2010-06       Impact factor: 6.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.